Core Insights - The PD-(L)1 inhibitor industry is at a pivotal development point, with Hansai Aitai (3378.HK) breaking through traditional frameworks through innovative mechanisms, particularly with its two key pipelines, HX009 and HX044, marking a new chapter in tumor immunotherapy [1] Group 1: Product Innovations - HX009 is a bispecific antibody fusion protein targeting both CD47 and PD-1, achieving historic breakthroughs by reactivating exhausted T cells and demonstrating superior anti-tumor activity compared to traditional therapies [2] - HX009 has shown excellent safety at a dosage of 10 mg/kg, with no severe hematologic toxicity, and has demonstrated clear clinical activity in refractory patients previously treated with PD-1 [2] - HX044, the world's first CTLA-4/CD47 bispecific antibody, utilizes a unique design to optimize dual-target affinity, effectively targeting Treg cells within tumors while preserving peripheral normal Treg and red blood cells [2] Group 2: Clinical Development - HX009 has successfully completed Phase I clinical trials and is advancing rapidly into Phase II studies for multiple cancers, including advanced melanoma and EBV-positive non-Hodgkin lymphoma, and has been approved for combination therapy with Enhertu for advanced triple-negative breast cancer [2] - HX044 has initiated clinical trials in Australia and China and has been approved for use in combination with PD-1 for treating advanced solid tumors, potentially reshaping the competitive landscape of solid tumor immunotherapy [2][3] Group 3: Competitive Advantage - Hansai Aitai has established an unreplicable core competitive advantage through forward-looking mechanism exploration, disruptive molecular design, and solid clinical data, effectively addressing the toxicity issues of traditional CD47 therapies [3] - The company aims to continue deepening its exploration of the new CD47 mechanism and accelerate the clinical translation of more innovative drugs, leveraging its strong pipeline value to empower industry development [3]